Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China
Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has...
July 2025
Merck Initiates EXPrESSIVE Phase III Trial for Once-Monthly HIV PrEP Drug MK-8527
Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) announced the initiation of the EXPrESSIVE Phase...
China Medical System’s CMS-D001 Gains NMPA Approval for Atopic Dermatitis Trials
China Medical System Holdings Limited (CMS; HKG: 0867) announced that it has received clinical trial...
NHSA Reports 2024 Healthcare Stats: BMI Fund Reaches RMB 3.49 Trillion Income with 95% Participation Rate
The National Healthcare Security Administration (NHSA) this week released its national medical and healthcare development...
SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data
SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA)...
Mabwell Signs Licensing Agreement with Unilab for Denosumab Biosimilars in the Philippines
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with Unilab, Inc.,...
Innovent Biologics and JD Health Form Strategic Partnership to Enhance Drug Supply and Healthcare Services
China-based Innovent Biologics Inc., (HKG: 1801) and JD Health International Inc., (HKG: 6618) have officially...
Shanghai Henlius Biotech Initiates US Patient Dosing in Phase III Trial for HER2-Positive Gastric Cancer
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) announced the first patient dosing in the US...
Bayer AG’s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction ≥40%
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from...
Sichuan Biokin’s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma
China’s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...
Hunan Mabgeek Biotech Files for Hong Kong IPO to Expand Innovative Biologics Pipeline
China-based Hunan Mabgeek Biotech Co., Ltd has submitted an application to the Hong Kong Stock...
GSK’s Arexvy RSV Vaccine Expansion for Adults 18-49 Receives FDA Review
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has...
Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name:...
Boao Super Hospital Introduces Xiaflex for Non-Surgical Peyronie’s Disease Treatment
Boao Super Hospital in Hainan last week successfully introduced Xiaflex (collagenase clostridium histolyticum), a nonsurgical...
Lexenpharm Partners with AptarGroup for Single-Dose Nasal Spray Services in Greater China
China-based Lexenpharm late last week announced a strategic partnership with Aptar Pharma, a US-based global...
Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development
US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ:...
Royal Philips and Suzhou Peixin Collaborate on AI-Powered Interventional Therapy Platform for Structural Heart Disease
Dutch device giant Royal Philips (NYSE: PHG) and China-based Suzhou Peixin Technology Co., Ltd. late...
YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study
Shanghai-based YolTech Therapeutics announced that it has received clearance from the National Medical Products Administration...
CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings...
Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China
Japan-based Eisai (TYO: 4523) announced the official commercial release of the first batch of its...